Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
37.00    0.00 (0.00%)
Bid:
35.00
Ask:
39.00
Spread: 4.00 (11.429%)
Market Cap: £17.23m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

Block Listing Return

1 Oct 2025 07:00

RNS Number : 4666B
Cambridge Cognition Holdings PLC
01 October 2025
 

1 October 2025

 

Cambridge Cognition Holdings plc

 

("Cambridge Cognition", the "Company" or the "Group")

 

Block Listing Return

 

The Company makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:

 

Name of applicant:

Cambridge Cognition Holdings plc

Name of scheme:

Share Options

Period of return:

From:

1 April 2025

To:

30 September 2025

Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission:

1,000,000 ordinary shares of £0.01 each in the Company admitted to trading on 23 March 2023

Balance of unallotted securities under scheme(s) from previous return:

466,316 ordinary shares

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Nil

Less:  Number of securities issued/allotted under scheme(s) during period:

Nil

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

466,316 ordinary shares

 

Name of contact:

Simon McKeating

Telephone number of contact:

+44 (0)1223 810700

 

Enquiries:

 

Cambridge Cognition Holdings plc 

Rob Baker, Senior Executive Director and Group Chief Operating Officer

 

Tel: 012 2381 0700 

press@camcog.com 

Panmure Liberum Limited (NOMAD and Joint Broker)

Will Goode / Mark Rogers / Freddy Crossley

Rupert Dearden 

Tel: 020 7886 2968

(Corporate Finance)

(Corporate Broking)

 

Dowgate Capital Limited (Joint Broker) 

David Poutney / Amber Higgs

 

Tel: 020 3903 7715 

 

 

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specialising in digital health products that advance brain health research and treatment.

Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:

· Clinical Studies for new pharmaceuticals;

· Academic Research for scientists to understand CNS disorders;

· Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,

· Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: www.cambridgecognition.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLREALNEDEDSEFA
Date   Source Headline
15th Dec 20149:21 amRNSDirector/PDMR Shareholding
21st Nov 20145:13 pmRNSDirector Declaration
30th Oct 20147:00 amRNSSupporting the Dementias Research Platform UK
23rd Oct 20147:00 amRNSLaunch of CTIS-Profile 2+ on Cantab Connect
1st Oct 20147:00 amRNSDirector/PDMR Shareholding
29th Sep 201412:40 pmRNSReplacement - Director/PDMR Shareholding
29th Sep 201410:06 amRNSDirector/PDMR Shareholding
24th Sep 201410:22 amRNSHolding(s) in Company
24th Sep 20147:00 amRNSDirector/PDMR Shareholding
23rd Sep 20141:29 pmRNSHolding(s) in Company
18th Sep 201411:57 amRNSIssue of Equity
11th Sep 20147:00 amRNSHalf Yearly Report
13th Aug 20147:00 amRNSExpands collaboration with Altreos
15th Jul 20147:00 amRNSNew research delivered at AAIC
3rd Jul 20144:58 pmRNSHolding(s) in Company
2nd Jul 20147:00 amRNSHalf Year Pre-Close Update
26th Jun 20147:00 amRNSHuman Abuse and Liability trial contracts won
5th Jun 20147:00 amRNS£1.6m phase III cognitive safety trial
3rd Jun 20147:00 amRNSLaunch of first two products on new platform
28th May 20147:00 amRNSCantab Mobile rolled out in NE Lincolnshire CCG
8th May 201411:03 amRNSResult of AGM
8th May 20147:00 amRNSAGM Statement
10th Apr 201411:41 amRNSPosting of Annual Report & Notice of AGM
2nd Apr 20147:00 amRNSDirectorate Change
14th Mar 20147:00 amRNSNesta report features Cambridge Cognition
13th Mar 20147:00 amRNSFinal Results
11th Mar 20147:00 amRNSProfessor Trevor Robbins wins 'The Brain Prize'
3rd Mar 20147:00 amRNSNew software launched for cognitive research
9th Jan 20147:00 amRNSAppointment of Director
16th Dec 20137:00 amRNSDavid Cameron References Cambridge Cognition
26th Nov 20137:00 amRNSCEO Review and Update
18th Sep 20137:00 amRNSHalf Yearly Report
14th Aug 20137:00 amRNSDirectorate Change
26th Jun 20137:00 amRNSProgress update on CANTABmobileT
18th Jun 20131:04 pmRNSHolding(s) in Company
19th Apr 20137:00 amRNSNHS Commissioning Board sets new DES for dementia
18th Apr 20137:00 amRNSAdmission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.